Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm - Tremoulet, Adriana H.; Jain, Sonia; Jone, Pei-Ni; Best, Brookie M.; Duxbury, Elizabeth H.; Franco, Alessandra; Printz, Beth; Dominguez, Samuel R.; Heizer, Heather; Anderson, Marsha S.; Glodé, Mary P.; He, Feng; et al. (The Journal of pediatrics, 2019)
Keywords: Administration, Oral; Adolescent; atorvastatin; Atorvastatin - administration & dosage; Atorvastatin - adverse effects; Atorvastatin - pharmacokinetics; Child; Child, Preschool; Coronary Aneurysm - drug therapy; Coronary Aneurysm - etiology; coronary artery abnormalities; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics; Kawasaki disease; Male; Mucocutaneous Lymph Node Syndrome - complications; Mucocutaneous Lymph Node Syndrome - drug therapy; statin; CRP; FDA; DSMB; iTreg; ALT; DLT; TNF; ASA; Kawasaki disease; nTreg; HUVEC; CA; coronary artery abnormalities; Zmax; Cmax; AST; CAA; IL; AE; LCWE; Treg; CK; IVIG; RCHSD; atorvastatin; mDC; PBMC; LAD; MMP; RCA; statin; SAE; Tmax; 24-OHC; PK; MTD; ELISA